Phase 1 × Completed × Lymphoma, T-Cell, Peripheral × Clear all Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Phase 1 Completed
26 enrolled 24 charts
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Phase 1 Completed
23 enrolled
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Phase 1 Completed
26 enrolled
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Phase 1 Completed
14 enrolled
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
Phase 1 Completed
20 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase 1 Completed
16 enrolled
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Phase 1 Completed
15 enrolled
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Phase 1 Completed
21 enrolled
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Phase 1 Completed
16 enrolled 16 charts
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Phase 1 Completed
286 enrolled 26 charts
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Phase 1 Completed
26 enrolled 19 charts
EpiBrentlen
Phase 1 Completed
6 enrolled
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
Phase 1 Completed
11 enrolled 16 charts
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Phase 1 Completed
15 enrolled 18 charts
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Phase 1 Completed
48 enrolled
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
Phase 1 Completed
11 enrolled
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Phase 1 Completed
24 enrolled
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Phase 1 Completed
33 enrolled
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
Phase 1 Completed
29 enrolled
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Phase 1 Completed
58 enrolled 15 charts
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Completed
23 enrolled
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients
Phase 1 Completed
30 enrolled
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Phase 1 Completed
18 enrolled
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Phase 1 Completed
44 enrolled
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
27 enrolled
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Completed
17 enrolled
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
20 enrolled
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Phase 1 Completed
6 enrolled
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
Phase 1 Completed
34 enrolled
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Phase 1 Completed
8 enrolled
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Completed
36 enrolled